{"id":8,"date":"2007-03-24T10:03:19","date_gmt":"2007-03-24T09:03:19","guid":{"rendered":"http:\/\/www.i-base.info\/qa\/?p=8"},"modified":"2021-11-22T12:19:04","modified_gmt":"2021-11-22T12:19:04","slug":"are-there-new-treatments-available-for-drug-resistant-hiv","status":"publish","type":"post","link":"https:\/\/i-base.info\/qa\/8","title":{"rendered":"Are there new treatments available for drug resistant HIV?"},"content":{"rendered":"<p>There is a lot of information about treatment of drug-resistant HIV in        the i-Base guide <a href=\"https:\/\/i-base.info\/guides\/changing\/\">Changing Treatment: second line therapy &amp; drug resistance<\/a>.<\/p>\n<p>Please let us know if you&#8217;d like us to send you a print copy.<a href=\"http:\/\/www.i-base.info\/guides\/changing\/index.html\"><br \/>\n<\/a><\/p>\n<p>This guide was updated in April 2007 so includes information        about the next new drugs, many of which are already available in Europe        on expanded access programmes.<\/p>\n<p>This includes a new integrase inhibitor called raltegravir (formally MK-0518),        and new CCR5 inhibitor (called maraviroc), a new protease inhibitor darunavir        (formally, TMC-114 and this month approved in Europe) and a new NNRTI called        etravirine (formally TMC-125).<\/p>\n<p>If you have never used a drug from a new class: integrase inhibitors, CCR5        inhibitors, or, for many people, fusion inhibitors, then they will all work        against HIV that is resistant to drugs from the first three classes of drugs:        nukes, NNRTIs and protease inhibitors.<\/p>\n<p>To answer your second question, the key to chance of survival for people        with drug resistance, is that with these new treatment the chance is very        very promising. You need to make sure that each of these drugs are only        used in combinations that include at least another two drugs that are also        definitely active.<\/p>\n<p>This will probably include using them together, or using them with a fusion        inhibitor called T-20. This is because all these new drugs are also vulnerable        to resistance if other drugs in the combination are not active.<\/p>\n<p>In a study reported at a conference last month, 98% of people using raltegravir,        darunavir and T-20 for the first time, (a sub group of a larger raltegravir        trial) were able to get there viral load reduced to less than 400 copies\/mL        after 16 weeks.<\/p>\n<p>I&#8217;m not sure which country you live in, but I assumed that your email was        from Europe, the US or a Western country with access to these drugs.<\/p>\n<p>If you are writing from a country that has more limited access to treatment,        the principles of choosing new drugs are similar but your individual treatment        history becomes much more important in deciding which drugs may work from        nukes, NNRTIs and protease inhibitors. Information in the guide above still        covers this.<\/p>\n<p>Please write with more details if this is the case, and I can reply either        online, or confidentially by private email.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Are there new treatments available for drug resistant HIV?<\/p>\n<p>What is the chance of survival for people who are infected with drug resistant HIV?<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,10,35],"tags":[],"class_list":["post-8","post","type-post","status-publish","format-standard","hentry","category-all-topics","category-changing-treatment","category-resistance"],"_links":{"self":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts\/8","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/comments?post=8"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts\/8\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/media?parent=8"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/categories?post=8"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/tags?post=8"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}